Your browser does not support JavaScript! >

Better exploit protein-protein interaction (PPI) interfaces for drug discovery

With twin platform technologies, Interprotein provides highly active modulators for protein-protein interaction (PPI) targets.

Our proprietary technology (INTENDD®) is built upon a different conceptual foundation from MD-based docking simulation methods, generating highly active compounds with unique scaffolds.

On the other hand, our newly constructed libraries of helix-loop-helix peptide achieved a near 100% success rate in identifying strong binders with KD values in low nanomolar range.

Change drug discovery

At Interprotein, we strive to revolutionize drug discovery with our expertise in analyzing and exploiting protein-protein interaction (PPI) interfaces to design and create PPI modulators. Targeting PPIs for therapeutic intervention with small molecules have long been postulated as plausible, but the number of authentic PPI inhibitors on the market is limited.

As the success of therapeutic antibodies shows, PPIs are proven targets especially for cell surface receptors and growing interests are being focused on PPI modulators in the increasingly difficult R&D environment in drug discovery due to less and less druggable targets after easy targets are already harvested. Protein-protein "interactomes" predict the number of putative PPIs in the range between 130,000 to 650,000. Therefore, we are actually seeing a sea of druggable targets in front of us. Yet, many of us are still struggling to exploit PPI interfaces for the development of PPI modulators.

We believe that we can change this situation with our twin proprietary technologies; INterprotein’s ENgine for new Drug Design, (INTENDD®) , a structure-based drug discovery (SBDD) strategy for small molecules, and helix-loop-helix peptide, a conformationally-constrained peptide with a unique modality.

INTENDD®

With INTENDD®, we aim to develop and provide an in silico drug design platform specialized for producing small molecule PPI modulators, and extend this technology to establish an AI-based drug discovery program.

Helix-loop-helix peptide

Alternatively, we have developed extremely diverse libraries of helix-loop-helix peptides for phage-display screening. Phage-displayed random peptide screening enables us to achieve a near 100% success rate in identifying active peptides with high affinity and high specificity to PPI targets. In addition, we can easily modulate pharmacokinetic profiles via multiple approaches.

Our promise

Through collaborative R&D efforts, we will fully exploit our twin technologies for small molecules and peptides to identify highly active modulators against previously intractable PPI interfaces. We commit to turning current biologics (antibodies and soluble receptors)-based PPI inhibitions into more patient-friendly therapies with small molecule and/or peptide PPI modulators to change patients’ lives.

What's New

Sep.21,2017 A banner to the webpage of Biocomo is added.
Aug.21,2017 Dr. Takeshi Tanaka, the manager of Drug Design lab, published an article in the journal of Medical Science Digest.
Jul.21,2017 We have renewed our web site! and also started Twitter, please follow us!
Jul.18,2017 Dr. Matsuzaki, the head of Drug Design lab, contributed a section to the Encyclopedia of Artificial Intelligence (The Japanese Society for Artificial Intelligence Edition), which was published on July 10, 2017.
Jul.11,2017 On July 25th, Masato Hosoda, CEO, will give a presentation at the KANSAI seminar titled “Kansai in the new era opened by AI” hosted by BBTower, Inc.
Jul.06,2017 On July 24th, Masaro Hosoda, CEO, will give a presentation at a symposium entitled “Realization of a society of health and longevity via application of AI and Big-data” hosted by Institution for Biomedical Research and Innovation (IBRI)
Jul.05,2017 On July 7th, Masato Hosoda, CEO, will give a presentation at “Mie university - jurisprudence and medical science joint symposium” hosted by Graduate School of Medicine, Mie University
May.30,2017 Dr. Matsuzaki, the head of Drug Design Lab, gave a poster presentation titled “True landscape of drug-protein binding” at JCUP VIII, an annual science meeting held by OpenEye Scientific Software.
Sept.20,2016 New York Medical College and Interprotein Announce Research Partnership Agreement on Drug Discovery Research for small molecule PPI Inhibitors
Apr.25,2016 Interprotein Corporation and A.I. Squared, Inc. Sign a Joint Research and Development AI Drug Discovery Agreement